Stimulation of the release of endothelium-derived relaxing factor (EDRF) in the kidney has been shown to result in natriuresis without affecting glomerular filtration rate. This may be due to EDRF directly regulating solute transport in the cortical collecting duct (CCD). To test this hypothesis, we measured the effect of bradykinin (Bk) 
Introduction
Endothelium-dependent relaxation of blood vessels results from the release ofa diffusible substance with a plasma half-life of < 30 s, termed endothelium-derived relaxing factor (EDRF) . ' Experimental evidence suggests that EDRF may be 1 . Abbreviations used in this paper: Ach, acetylcholine; BK, bradykinin; CCD, cortical collecting duct; CPAE, cow pulmonary artery endothelial; EDRF, edothelium-derived relaxing factor; IS,, short-circuit current; M-1, a CCD cell line; N-Arg, nitroarginine; PD, transepithelial potential difference.
either NO (1) or a nitrosothiol such as s-nitrosocysteine (2, 3).
The synthesis of EDRF is thought to be from the amino acid L-arginine (4); and its release can be stimulated by a variety of agents, including bradykinin (Bk) and acetylcholine (Ach) (1, 5) . L-N0-nitroarginine (N-Arg), a guanidino-substituted L-arginine analogue, is a competitive inhibitor of EDRF synthesis (6) . The mechanism of action of EDRF in vasorelaxation involves activation of soluble guanylate cyclase, which causes intracellular cGMP to increase (7, 8) . Inhibition of soluble guanylate cyclase by methylene blue blocks EDRF-induced relaxation (9) .
Intrarenal infusion of Bk or Ach, resulting in release of EDRF, has been shown to cause diuresis and natriuresis without affecting glomerular filtration rate (10, 1 1) . This may be due to EDRF mediation of hemodynamic changes, a direct inhibition of tubular transport, or both. Although no direct action ofEDRF inhibiting transport in individual nephron segments has been reported to date, it is an intriguing possibility since cGMP, which has been shown to act as EDRF's second messenger (7, 8) , also inhibits transport in the collecting duct. Atrial natriuretic factor, which acts by increasing intracellular cGMP content (12) , inhibits both sodium and water transport in the cortical and inner medullary collecting duct (13) (14) (15) The bioassay ring was stretched under direct superfusion in a stepwise manner until the response to 20 mM KCl was optimal (average 8 g). The removal of the endothelium was demonstrated by the absence ofrelaxation to Bk (10-8 M) under direct superfusion, after precontraction with PGF2, (I0-M). All experiments were done in the presence of indomethacin (10-i M) to block PG synthesis (see reference 17 for review of the method).
Electrophysiology. I,, was measured in M-1 monolayers in an Ussing-type chamber as previously described (16 collected and frozen at -700C until the day ofthe assay. On the day of the assay, the acid was extracted from the samples with water-saturated ether. The samples were dried under N2 gas at room temperature, reconstituted in buffer, and assayed for cGMP using a kit from Biomedical Technologies Inc., Stoughton, MA. A total of four assays was run, and samples were run in duplicate. The inter-and intraassay coefficients of variation were 12.2 and 6.5%, respectively. The detectable range was 4-400 fmol. To examine the recovery of cGMP during the extraction process, 150 fmol of cGMP in 300 M1 of TCA was added to permeable collagen membranes (without cells); 94±2.5% of it was recovered. Recoveries were monitored in each experiment.
Statistics. Values are reported as the mean±SE. Individual culture dishes were considered as an n value of 1. Data from transport studies were evaluated with analysis ofvariance for repeat measures and multiple paired t tests with a Bonferroni adjustment to determine significant differences between each ofthe treatments. Data from cGMP measurements were evaluated using analysis of variance with three factors and multiple unpaired t tests with Bonferroni adjustment to determine significant differences between treatment groups. A . 95% probability that the means were different was considered significant.
Results
Bioassay ofEDRFproduction by CPAE cells. To demonstrate that our cultured CPAE cells release EDRF, we examined their ability to relax precontracted vascular rings (Fig. 1) Electrophysiology. To examine the effects of Bk alone on transport in M-l cells, Bk was added to the bath and lumen of M-l cultures in doses of 10-5, 10-6, 10-7, 10-8, and I0-`M (Fig.  2) . Bk did not affect I. or PD at doses < 10-6 M. To ensure against a direct effect of Bk, a dose 1,000-fold less than that necessary to elicit a response was used.
The effects ofBk on I, and PD were measured in cultures of M-I cells in the presence ofCPAE cells. The addition ofCPAE cells to M-l cultures did not affect ISC (Fig. 3) . Baseline ISC in M-1 monolayers was 47±4 ,A/cm2 before CPAE cell addition and 43±4.5 MA/cm2 after addition. PD decreased slightly but significantly, from -20±1 to -16±2 mV (P <0.01). The subsequent addition of Bk inhibited ISC from 43±4.5 to 26±4 gA/ cm2, a 40+6% decrease (P < 0.001) (Fig. 3) . PD ing 10 Addition of methylene blue (I0-M) alone to M-1 cultures had no significant effect on ISC (51±2 to 54±1 ,uA/cm2) or PD (-37±2 to -39±2 mV). Addition of Bk (10-9 M) to methylene blue-treated M-1 cells in the presence of CPAE cells also produced no significant effect on IS, (54±0.5 to 56±0.5 AA/ cm2) or PD (-40±1 to -39±1 mV).
cGMP content. The cGMP contents of CPAE cells alone and those stimulated with Bk were below the limits of detectability (< 4 fmol). The cGMP content of the media was also below detectable limits (Fig. 5) 
Discussion
Our study demonstrated that Bk or Ach addition to M-l cells, in the presence of CPAE cells, decreased transport and increased cGMP content. Inhibition oftransport was blocked by N-Arg, a competitive inhibitor of EDRF synthesis (6), and methylene blue, an inhibitor of soluble guanylate cyclase (9) . Stimulation of cGMP content in M-1 cells was also partially blocked by N-Arg.
EDRF is a mediator of vascular tone and therefore participates in the regulation of peripheral resistance and, consequently, blood pressure. EDRF may also regulate blood pressure via effects on fluid and solute excretion in the kidney. It has been shown that stimulation ofEDRF release in the kidney induces a natriuresis and diuresis without affecting glomerular filtration rate (10, 1 1) . This would suggest that EDRF either has direct renal tubular effects on sodium reabsorption or causes hemodynamic effects that alter sodium reabsorption. know of no studies that directly address these possibilities believe the present study provides the first evidence that RF has an effect on transport in cultured CCD cells. (22); however, since N-Arg and methylene blue blocked the inhibition oftransport caused by Bk or Ach in the presence of CPAE cells, this would suggest that the inhibition was specifically due to the release ofEDRF. Furthermore, cGMP has been proposed to be the second messenger of EDRF in smooth muscle (7, 8) ; therefore, the observation that cGMP was stimulated by the addition of Bk in cultures of M-1 and CPAE cells further supports the contention that EDRF is involved. The M-1 cell line possesses many antigenic and differentiated transport properties of the CCD epithelium (16); therefore, the EDRF-stimulated inhibition of transport observed in the M-1 cells is probably also expressed in vivo. It is true, however, that phenomena that occur in cultured cells provide only indirect evidence that the indicated response is indeed physiological; thus, further studies are required in order to determine whether EDRF has direct tubular effects in vivo.
In conclusion, EDRF release from CPAE cells decreased transport in M-1 CCD cells and increased cGMP levels. This decrease in transport may account for the renal effects evoked by EDRF in in vivo studies.
